Risk factors
GRAIL (GRAL) risk factors
Item 1A of every GRAIL, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
67 risks, 10 new, 10 dropped, 20 reworded since the prior year. The failed NHS-Galleri trial endpoints dominate new disclosures, threatening commercial adoption, reimbursement, and stock price stability.
Filed Mar 12, 2026 - FY2024 10-K risk factors
67 risks. Grail faces massive net losses, reaching $2.0 billion in fiscal 2024, driven by research and commercialization of its Galleri cancer test.
Filed Mar 05, 2025